Response by Andreas et al to Letter Regarding Article, "Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial".

Martin Andreas, Roxana Moayedifar, Georg Wieselthaler, Michael Wolzt, Julia Riebandt, Thomas Haberl, Philipp Angleitner, Thomas Schlöglhofer, Dominik Wiedemann, Heinrich Schima, Guenther Laufer, Daniel Zimpfer

Journal: Circulation. Heart failure 2019;10(10):e004309

PMID: 29030374

Full Text on Atypon View on PubMed

Abstract

Address: From Division of Cardiac Surgery (M.A., R.M., J.R., T.H., D.W., G.L., D.Z.), Department of Clinical Pharmacology (M.W.), and Center for Medical Physics and Biomedical Engineering (T.S., H.S.), Medical University of Vienna, Austria; and Division of Adult Cardiothoracic Surgery, University of California, San Francisco School of Medicine (G.W.).

DOI: 10.1161/CIRCHEARTFAILURE.117.004309

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/29030374

Subscription / membership required

Full Text Sources:

MeSH Terms: Anticoagulants, Dabigatran, Heart-Assist Devices, Humans, Pilot Projects, Thromboembolism, Vitamin K